Korde LA, Somerfield MR, Hershman DL. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
PMID: 35417251